Actuate Therapeutics (ACTU) Competitors $8.72 +0.11 (+1.28%) Closing price 09/4/2025 04:00 PM EasternExtended Trading$8.65 -0.07 (-0.80%) As of 09/4/2025 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ACTU vs. GHRS, KURA, KALV, TYRA, BCAX, SNDL, IMTX, TERN, MRVI, and VIRShould you be buying Actuate Therapeutics stock or one of its competitors? The main competitors of Actuate Therapeutics include GH Research (GHRS), Kura Oncology (KURA), KalVista Pharmaceuticals (KALV), Tyra Biosciences (TYRA), Bicara Therapeutics (BCAX), SNDL (SNDL), Immatics (IMTX), Terns Pharmaceuticals (TERN), Maravai LifeSciences (MRVI), and Vir Biotechnology (VIR). These companies are all part of the "pharmaceutical products" industry. Actuate Therapeutics vs. Its Competitors GH Research Kura Oncology KalVista Pharmaceuticals Tyra Biosciences Bicara Therapeutics SNDL Immatics Terns Pharmaceuticals Maravai LifeSciences Vir Biotechnology GH Research (NASDAQ:GHRS) and Actuate Therapeutics (NASDAQ:ACTU) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, profitability, media sentiment, analyst recommendations, institutional ownership, risk, valuation and dividends. Which has higher earnings and valuation, GHRS or ACTU? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$38.96M-$0.74-18.99Actuate TherapeuticsN/AN/A-$27.28MN/AN/A Do insiders & institutionals believe in GHRS or ACTU? 56.9% of GH Research shares are held by institutional investors. 41.6% of GH Research shares are held by insiders. Comparatively, 69.3% of Actuate Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Do analysts rate GHRS or ACTU? GH Research currently has a consensus price target of $32.00, indicating a potential upside of 127.76%. Actuate Therapeutics has a consensus price target of $20.33, indicating a potential upside of 133.18%. Given Actuate Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Actuate Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 1 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.88Actuate Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is GHRS or ACTU more profitable? Actuate Therapeutics' return on equity of 0.00% beat GH Research's return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -16.71% -16.06% Actuate Therapeutics N/A N/A -281.83% Does the media prefer GHRS or ACTU? In the previous week, GH Research had 7 more articles in the media than Actuate Therapeutics. MarketBeat recorded 9 mentions for GH Research and 2 mentions for Actuate Therapeutics. GH Research's average media sentiment score of 0.81 beat Actuate Therapeutics' score of 0.71 indicating that GH Research is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GH Research 4 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Actuate Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryGH Research and Actuate Therapeutics tied by winning 5 of the 10 factors compared between the two stocks. Get Actuate Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACTU and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ACTU and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACTU vs. The Competition Export to ExcelMetricActuate TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$178.62M$3.13B$5.76B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8975.7126.43Price / SalesN/A458.96548.17119.09Price / CashN/A44.5237.0558.92Price / Book872.009.9311.296.06Net Income-$27.28M-$53.38M$3.29B$266.28M7 Day Performance3.32%0.63%0.18%-0.33%1 Month Performance19.29%6.31%6.30%3.43%1 Year Performance6.99%11.63%56.91%23.10% Actuate Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACTUActuate Therapeutics2.659 of 5 stars$8.72+1.3%$20.33+133.2%+6.5%$178.62MN/A0.0010GHRSGH Research2.436 of 5 stars$13.13-0.4%$32.00+143.8%+65.9%$682.89MN/A-17.7410News CoverageKURAKura Oncology3.8371 of 5 stars$7.56-1.2%$24.10+218.8%-59.0%$657.42M$53.88M-3.35130News CoveragePositive NewsAnalyst ForecastKALVKalVista Pharmaceuticals4.0501 of 5 stars$13.08+0.7%$26.29+101.0%+17.6%$657.19MN/A-3.54100News CoverageTYRATyra Biosciences2.7652 of 5 stars$12.34+2.8%$30.83+149.8%-43.0%$654.26MN/A-6.9020News CoveragePositive NewsAnalyst ForecastBCAXBicara Therapeutics2.5936 of 5 stars$11.72+3.5%$32.25+175.2%N/A$637.30MN/A-3.6832Positive NewsSNDLSNDL3.4933 of 5 stars$2.43+1.0%$4.00+64.9%+20.8%$637.23M$944.25M-8.982,516News CoverageAnalyst ForecastIMTXImmatics2.4227 of 5 stars$5.22-0.3%$14.67+181.2%-49.1%$635.83M$130.13M-8.05260Positive NewsTERNTerns Pharmaceuticals3.9601 of 5 stars$7.06+5.5%$15.63+121.5%-3.7%$617.39MN/A-6.7840News CoveragePositive NewsAnalyst ForecastMRVIMaravai LifeSciences3.6883 of 5 stars$2.41+0.2%$5.75+139.1%-71.1%$612.46M$219.83M-1.77610Positive NewsOptions VolumeVIRVir Biotechnology3.2013 of 5 stars$4.41+0.6%$30.25+586.7%-32.4%$611.93M$14.39M-1.10580News CoverageAnalyst ForecastInsider Trade Related Companies and Tools Related Companies GHRS Competitors KURA Competitors KALV Competitors TYRA Competitors BCAX Competitors SNDL Competitors IMTX Competitors TERN Competitors MRVI Competitors VIR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ACTU) was last updated on 9/5/2025 by MarketBeat.com Staff From Our Partners“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has bee...InvestorPlace | SponsoredHow “Trump’s New Dollar” Could Impact Your WealthPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredOne tiny company just cracked Google’s $19B problemFor decades, this “AI metal” was trapped in labs, too slow and expensive to ever reach mass production. The...True Market Insiders | SponsoredWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Actuate Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Actuate Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ACTU Stock Alerts